[Press release – not published yet] Monoclonal antibodies reduced hospitalizations and death in Phase 3 trial for early COVID-19
11 Mar, 2021 | 08:41h | UTCPress release: Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Commentary: Eli Lilly’s combo therapy for COVID-19 cuts serious illness and death in large study – Reuters